摘要:

AbstractThe approach to the possible causative factors of colorectal cancer has changed substantially during the last 20 years. The enthusiasm aroused by the Burkitt's fiber hypothesis [1] is today partly overcome by the contradictory results from analytical studies and by the trends emerging from descriptive epidemiology. In addition, the identification of precursor lesions, such as adenomas, is shifting the interest of researchers to earlier stages of the natural history of these cancers, in the attempt to link risk factors to the development and progressions of adenomas.

ISSN:0022-4790    

DOI:10.1002/jso.2930480502

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

摘要:

AbstractColorectal carcinoma is one of the most common malignancies and has a considerable mortality with an overall 5‐year survival of about 50%. Adjuvant chemotherapy and radiotherapy have not significantly changed survival rates. It is therefore mandatory for this tumor type, as for all tumors refractory to clinical treatment, to intensify the effort to define risk factors of incidence and disease progressio

ISSN:0022-4790    

DOI:10.1002/jso.2930480503

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

摘要:

AbstractMonoclonal antibodies (MAbs) which recognize a human tumor antigen, termed tumor‐associated glycoprotein‐72 (TAG‐72), have successfully been used to localize primary as well as metastatic colorectal tumor lesions in patients. The localization of the anti‐TAG‐72 MAbs has also been exploited intraoperatively using a hand‐held gamma probe. That procedure, termed radioimmunoguided surgery (RIGS), has identified occult tumors which were not detected using standard external imaging techniques. In another clinical trial, interferon‐γ (IFN‐γ) was administered intraperitoneally to patients diagnosed with either gastrointestinal or ovarian carcinoma with secondary ascites. Analysis of the tumor cells isolated from the malignant ascites revealed a substantial increase in TAG‐72 expression on the surface of tumor cells isolated from seven of eight patients. The results provide evidence that the combination of an anti‐carcinoma MAb with the administration of a cytokine, such as IFN‐γ, may be an effective approach for the detection and subsequent treatment,

ISSN:0022-4790    

DOI:10.1002/jso.2930480504

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

摘要:

AbstractColorectal cancer still represents one of the most important challenges in the field of cancer chemotherapy. The results obtained thus far with the combination of potentially active drugs have been very disappointing.

ISSN:0022-4790    

DOI:10.1002/jso.2930480505

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

摘要:

AbstractA novel tumor marker, tumor‐associated glycoprotein‐72 (TAG‐72), has been identified using monoclonal antibody (MAb) B72.3. Using immunohistochemical techniques, TAG‐72 has been found in carcinomas of various origin including colon, stomach, breast, lung, prostate, and ovary, as well as in body fluids. The presence of TAG‐72 in serum samples from 260 patients with colorectal disease (malignant or benign) has been evaluated using the CA72‐4 assay. Approximately 40% of patients with colorectal cancer exhibit elevated levels of this marker; moreover, the presence of positive levels of TAG‐72 significantly correlates with advanced stages of disease, suggesting that TAG‐72 may be a good marker of advanced colorectal cancer. Only 2% of the patients diagnosed with colorectal disease had elevated TAG‐72 serum levels indicating the high specificity of this marker. A comparative study with carcinoembryonic antigen (CEA) serum levels showed a complementarity of the two tumor markers; in fact, 49.6% of CEA negative cases scored positive for TAG‐72. A longitudinal evaluation of TAG‐72 serum levels in 31 patients with malignant disease was performed. The results indicate that patients with increasing TAG‐72 serum levels postoperatively may be indicative of recurrent disease. In 60% of patients in which significant changes of CEA levels could not be detected, TAG‐72 showed rising positive levels prior to clinical evidence of recurrent disease. These results suggest that the simultaneous use of TAG‐72 and CEA serum markers may be useful in the diagnosis of recurrent disease and therefore play an important role in the clinical ma

ISSN:0022-4790    

DOI:10.1002/jso.2930480506

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

摘要:

AbstractThe role of surgery in the treatment of large bowel cancer is still preeminent, influencing both the immediate and longer term outcome of the disease.

ISSN:0022-4790    

DOI:10.1002/jso.2930480507

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

ISSN:0022-4790    

DOI:10.1002/jso.2930480508

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

ISSN:0022-4790    

DOI:10.1002/jso.2930480509

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

摘要:

AbstractColorectal cancer recurrence may be conceptualized as resulting from two entirely different mechanisms. First, metastases through endothelial‐lined channels occur to both lymphatic and hematogenous routes. The cancers that disseminate in this fashion are metastatically inefficient. This dissemination occurs before the surgical resection of the primary cancer. Second, full thickness penetration of cancer through the bowel wall or, more frequently, intraperitoneal tumor emboli caused by the trauma of surgery result in implantation recurrence. This is seen at the resection site and on peritoneal surfaces. For the most part, this dissemination occurs at the time of surgical resection of the primary cancer. By changing the route (intraperitoneal vs. systemic) and timing (early postoperative vs. adjuvant) of chemotherapy administration this second mechanism of surgical treatment failure may be prevented. Phase II and pharmacologic studies suggest that improved survival and quality of life may occur with optimal use of early postoperative intraperitoneal chemotherap

ISSN:0022-4790    

DOI:10.1002/jso.2930480510

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY

ISSN:0022-4790    

DOI:10.1002/jso.2930480511

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1991

数据来源: WILEY